IMNM

Business Context and Reporting Period

Immunome, Inc. (IMNM) is a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class therapies, including antibody-drug conjugates (ADCs) and radioligand therapies. This Form 10-Q covers the quarterly period ended June 30, 2025. The company is currently advancing a pipeline that includes three clinical assets (varegacestat, IM-1021, and IM-3050) and three preclinical assets. As of June 30, 2025, the company had 87,045,008 shares of common stock outstanding.

Key Financial Metrics

Liquidity: The company reported a net cash increase of $0.6 million for the six months ended June 30, 2025. Management expects existing cash, cash equivalents, and marketable securities to fund operations for at least 12 months from the filing date.

Material Changes vs. Prior Period

• Revenue Growth: Collaboration revenue increased by 70% ($1.7 million) for the three months ended June 30, 2025, compared to the same period in 2024, driven by increased R&D activities allocated to the AbbVie collaboration. The AbbVie agreement terminated in July 2025, and all revenue under the contract has been recognized.
• Expense Reduction (Six Months): Total operating expenses decreased by $77.6 million for the six months ended June 30, 2025, compared to 2024. This significant decrease is primarily due to the absence of $118.3 million in in-process research and development (IPR&D) expenses recorded in 2024 related to asset acquisitions (Ayala and Zentalis).
• Net Loss Improvement: The net loss for the six months ended June 30, 2025, was $85.0 million, a reduction of $80.6 million compared to the $165.6 million loss in the prior year period, largely attributable to the non-recurring IPR&D charges in 2024.
• Capital Raise: In January 2025, the company completed a public offering of 22.3 million shares, raising net proceeds of $161.7 million.

Guidance, Outlook, and Risks

• Outlook: Immunome expects to continue incurring significant operating losses for the foreseeable future. The company anticipates that its current cash position will support operations for at least 12 months. Future funding will likely require additional equity offerings, debt financing, or strategic collaborations.
• Key Milestones:
  • Varegacestat: Phase 3 registrational trial enrollment completed in February 2024; topline data expected in the second half of 2025.
  • IM-1021: Phase 1 trial ongoing with first patient dosed in February 2025.
  • IM-3050: IND clearance received in April 2025; Phase 1 trial initiation expected in the second half of 2025.
• Risks and Contingencies:
  • Regulatory Approval: No products have been approved for commercial sale; success depends on clinical trial outcomes and regulatory approvals.
  • Capital Requirements: The company has an accumulated deficit of $600.8 million and requires substantial additional capital to advance its pipeline.
  • Third-Party Reliance: The company relies on third-party vendors for manufacturing and clinical trials, creating supply chain and execution risks.
  • Intellectual Property: Risks related to patent protection, enforcement, and potential infringement claims.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $268.1 million in liquid assets (cash + marketable securities) against the projected burn rate for the next 12 months.
• Revenue Sustainability: Confirm that no further revenue will be recognized from the terminated AbbVie collaboration and assess the timeline for any new commercial revenue.
• Clinical Data: Monitor the release of topline data for the varegacestat Phase 3 trial in the second half of 2025, which is critical for valuation.
• Dilution Risk: Review the remaining capacity under the 2024 ATM Agreement ($180 million) and potential future equity issuances required to fund operations.
• Expense Trends: Analyze the trajectory of R&D expenses as the company transitions from asset acquisition write-offs to ongoing clinical trial costs for multiple programs.